识别产后出血风险:针对贫血女性及临床评分系统
妊娠期缺铁性贫血影响全球38%女性,发展中国家高达50%,增加产后抑郁、早产、剖宫产、子痫前期和低出生体重风险。口服铁剂为经典治疗,静脉铁剂是不能耐受、无反应或孕晚期新诊断时的替代选择,管理缺铁性贫血对预防产后出血有保护作用。风险预测工具包括已开发的评估套件、列线图和机器学习模型,但低风险组预测有限,新工具仍需外部验证。
要点
- 妊娠期缺铁性贫血全球患病率38%,发展中国家高达50%,增加母婴不良结局风险。
- 静脉铁剂是口服铁剂不能耐受、无反应或孕晚期新诊断时的替代选择。
- 管理缺铁性贫血对预防产后出血有保护作用,风险预测工具仍需外部验证。
核心结论
- 管理缺铁性贫血对预防产后出血有保护作用,但现有风险预测工具在低风险组存在局限,新工具仍需外部验证后才能采用。
研究设计与样本
- 原文未报告研究设计,为综述性文章,检索范围未报告。
主要发现
- 妊娠期缺铁性贫血影响全球38%女性,发展中国家高达50%。
- 缺铁性贫血增加产后抑郁、早产、剖宫产、子痫前期和低出生体重风险。
- 口服铁剂为经典治疗,静脉铁剂是不能耐受、无反应或孕晚期新诊断时的替代选择。
- 已开发的风险评估套件对高危患者预测有用,但在低风险组存在局限。
- 列线图和机器学习工具正在探索中,部分列线图实施后证明有效,机器学习纳入既往未考虑的风险因素,但新工具仍需外部验证。
关键数值与推荐
- 缺铁性贫血定义在三个孕期各不相同,原文未给出具体阈值。
- 静脉铁剂适用于不能耐受口服铁剂、对口服铁剂无反应或孕晚期新诊断的患者。
临床怎么用
- 管理缺铁性贫血以预防产后出血,口服铁剂为经典治疗,静脉铁剂为特定情况下的替代选择。
- 使用风险评估套件识别产后出血高危患者,但需注意低风险组的预测局限。
- 新风险预测工具(列线图、机器学习)在测试条件下结果有前景,但采用前仍需外部验证。
局限性
- 风险评估套件在低风险组存在局限。
- 列线图和机器学习等新工具仍需外部验证后才能采用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Iron deficiency anemia during pregnancy is a common concern, affecting 38% of women worldwide and up to 50% in developing countries. It is defined differently throughout all 3 trimesters. It has several detrimental effects on pregnancy outcomes for both the mother and the fetus, such as increasing the risk for postpartum depression, preterm delivery, cesarean delivery, preeclampsia, and low birthweight. Management of iron deficiency anemia is done classically via oral iron supplementation. However, recent evidence has shown that intravenous iron is a good alternative to oral iron if patients are unable to tolerate it, not responding, or present with a new diagnosis very late in pregnancy. Management of iron deficiency anemia was demonstrated to be protective against postpartum hemorrhage. Other ways to prevent postpartum hemorrhage include improving prediction tools that can identify those at risk. Several risk assessment kits have been developed to estimate the risk for postpartum hemorrhage among patients and have been proven useful in the prediction of patients at high risk for postpartum hemorrhage despite limitations among low-risk groups. More comprehensive tools are also being explored by determining clinically relevant factors through nomograms, with some proving their efficacy after implementation. Machine learning is also being used to develop more complete tools by including risk factors previously not accounted for. These newer tools, however, still require external validation before being adopted despite promising results under testing conditions.
引用
- Faysal H, Araji T, Ahmadzia HK, et al. Recognizing who is at risk for postpartum hemorrhage: targeting anemic women and scoring systems for clinical use. Am J Obstet Gynecol MFM. 2022. PMID: 36075528. doi:10.1016/j.ajogmf.2022.100745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。